Can Seladelpar be taken for a long time and is it safe?

Seladelpar is a selective PPARδ agonist, mainly used to treat chronic hepatobiliary diseases such as primary biliary cholangitis (PBC). As a new type of drug targeting metabolic pathways, its therapeutic mechanism is relatively mild and does not directly suppress the immune system. Therefore, it theoretically has a certain basis for long-term use. Especially for those patients with PBC who have poor response or intolerance to ursodeoxycholic acid (UDCA), Siladepa is expected to become a sustainable alternative.

In multiple completed clinical trials, Siladepa has shown good tolerability and sustained efficacy. Research shows that when patients take 12 to 24 months, liver enzyme indicators such as A LP, ALT, etc. continued to decrease, and cholestasis symptoms were significantly relieved. At the same time, no serious adverse reactions or liver toxicity were observed, indicating that it has good long-term medication prospects. Additionally, discontinuation rates during treatment were low, indicating that most patients tolerated the drug long-term.

However, although the current data supports that Siladepa can be taken for a longer period of time, it is still necessary to pay attention to the potential risks caused by individual differences. A small number of patients may experience mild gastrointestinal reactions, fatigue or transaminase fluctuations and other adverse reactions, and individualized adjustments need to be made based on the results of regular examinations. Especially in patients with significantly abnormal liver function or other combined metabolic diseases, the safety of long-term medication should be carefully evaluated.

In short, the current research shows that Siladepa has the potential and safety for long-term use, but it still needs to be further verified in long-term observations in the real world. Rational use of medications under the guidance of a doctor and regular testing of liver function and metabolic indicators are the keys to ensuring long-term effectiveness and safety. As more follow-up data accumulates after marketing, Siladepa is expected to become one of the long-term treatment options in the management of chronic PBC.

Reference materials:https://www.drugs.com/